Investigational drug · Phase 3
SHR-1918
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
4 still active
All registered trials
10
Any phase or sponsor naming "SHR-1918"
First trial start
2023
Nov 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1918", any sponsor or status.
Conditions studied
As listed on its trial records.
- Homozygous Familial Hypercholesterolemia
- Hyperlipidemia
- Hypercholesterolemia
- Hypertriglyceridemia
- Hyperlipidemic
Approved drugs for the same conditions: High cholesterol · High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1918" as an intervention, largest first.
- A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemiaPivotal-lookingRecruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07230730 · 900 participants (planned) · Start Jan 13, 2026 · Primary completion Oct 2027
Drug: SHR-1918; SHR-1918 placebo · For: Hyperlipidemia
Sites: Hangzhou, China
- A Study of SHR-1918 In Participants With HypertriglyceridemiaPivotal-lookingActive, not recruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07349615 · 367 participants · Start Mar 31, 2026 · Primary completion Mar 2027
Drug: SHR-1918/ SHR-1918 placebo; SHR-1918/ SHR-1918 placebo · For: Hypertriglyceridemia
Sites: Shanghai, China
- Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemicPivotal-lookingCompleted
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06109831 · 335 participants · Start Nov 24, 2023 · Primary completion Jul 4, 2025
Drug: SHR-1918; SHR-1918 placebo · For: Hyperlipidemic
Sites: Hangzhou, China
- A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 InhibitorsPivotal-lookingRecruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07404553 · 126 participants (planned) · Start Apr 30, 2026 · Primary completion Jul 2028
Drug: SHR-1918 Injection; SHR-1918 Injection Placebo · For: Hypercholesterolemia
Sites: Nanjing, China
- Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07308392 · 119 participants · Start Feb 25, 2026 · Primary completion Jun 2027
Drug: HRS-7249 injection set; SHR-1918 injection set and 2 more · For: Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Sites: Nanjing, China
- Safety and Tolerability of SHR-1918 in Healthy SubjectsStatus unknown
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT05432544 · 72 participants · Start Jun 27, 2022 · Primary completion Dec 11, 2023
Drug: SHR-1918; SHR-1918 placebo · For: Hyperlipemia
Sites: Guangzhou, China
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaPivotal-lookingCompleted
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06723652 · 55 participants · Start Feb 13, 2025 · Primary completion Aug 25, 2025
Drug: SHR-1918; SHR-1918 placebo · For: Homozygous Familial Hypercholesterolemia
Sites: Changsha, China
- Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaNot yet recruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07133815 · 55 participants (planned) · Start Aug 2025 · Primary completion Dec 2025
Drug: SHR-1918 · For: Homozygous Familial Hypercholesterolemia
Sites: Changsha, China
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06471218 · 44 participants · Start Jul 2, 2024 · Primary completion May 16, 2025
Drug: SHR-1918; SHR-1918 Placebo · For: Hyperlipidemia
Sites: Meizhou, China
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT06009393 · 26 participants · Start Dec 22, 2023 · Primary completion Jun 29, 2024
Drug: SHR-1918 · For: Homozygous Familial Hypercholesterolemia
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Quarterly SHR-1918: End-of-Interval Activity-But for Whom?
Yang M, Xie X · JACC Asia 2026
- Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia.
Zhong W, Zhang J, Zhu D, et al. · JACC Asia 2026
- Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.
Corral P, Nardelli N, Schreier L · Curr Opin Endocrinol Diabetes Obes 2026
- Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.
Peng D, Wang L, Pi L, et al. · JAMA Cardiol 2026
- Antibody-Based Therapeutics for Hypercholesterolemia.
Tomlinson B, Chan P · Biologics 2025
- Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.
Hooper AJ, Parameswaran T, Burnett JR · Expert Opin Investig Drugs 2025
Also in development for Homozygous Familial Hypercholesterolemia
- ZodasiranAROANG3, VSA003Phase 33 trials
Arrowhead Pharmaceuticals · Homozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.